- Chugai and Nippon Shinyaku filed an MHLW regulatory application for Gazyva (obinutuzumab) for idiopathic nephrotic syndrome.
- INShore Phase III (global, randomized, open‑label) enrolled patients aged 2–25 with childhood‑onset INS, comparing Gazyva+oral steroids vs MMF+oral steroids.
- Primary endpoint was sustained complete remission through 52 weeks, with a statistically significant advantage for Gazyva and no new safety signals.
- Gazyva (obinutuzumab) is a glycoengineered type II anti‑CD20 monoclonal antibody, already approved in Japan for follicular lymphoma and CLL.
Regulatory filing
Chugai Pharmaceutical and Nippon Shinyaku submitted an application to Japan’s MHLW to expand approval of obinutuzumab (Gazyva) for idiopathic nephrotic syndrome based on Phase III INShore data.
INShore Phase III results
INShore was a global, multicenter, randomized open‑label trial in patients aged 2–25 with childhood‑onset INS (frequently relapsing or steroid‑dependent) comparing Gazyva+oral steroids versus MMF+oral steroids; the primary endpoint—sustained complete remission through 52 weeks—favored Gazyva with a statistically significant difference and no new safety signals versus the known profile.
Drug profile and mechanism
Gazyva (obinutuzumab) is a glycoengineered type II anti‑CD20 monoclonal antibody that depletes B cells; B‑cell depletion in INS is expected to suppress autoantibody production, modulate abnormal immune responses and reduce glomerular injury to support sustained remission; Gazyva is already approved in Japan for CD20‑positive follicular lymphoma and chronic lymphocytic leukemia.
Disease context
Idiopathic nephrotic syndrome is a primary nephrotic condition accounting for about 60% of cases overall and ~90% in pediatric patients; although many respond to steroids, frequent relapses or steroid dependence create a clinical unmet need due to long‑term steroid and immunosuppressant adverse effects, and severe INS may be designated an intractable disease in Japan.
